Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Takeda Pharmaceutical Co. Ltd. (TAK) Phase 3 PANTHER (Pevonedistat-3001) Trial Did Not Achieve Primary Endpoint
(NYSE: TAK) Delayed: 15.47 -0.16 (1.02%)
Previous Close $15.63    52 Week High $0.55 
Open $15.49    52 Week Low $0.55 
Day High $15.60    P/E N/A 
Day Low $15.39    EPS $-0.20 
Volume 2,351,300